# SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma

> **NCT03950271** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 25 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine

## Key facts

- **NCT ID:** NCT03950271
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-20
- **Primary completion:** 2024-01-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03950271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03950271, "SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03950271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*